SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
SUMMIT receives support from the Innovative Medicines Initiative Joint Undertaking under the grant agreement n° , resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.
IMI is a public/private partnership between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Each of the partners contributes with one billion EURO to the IMI budget for research grants. While the budget allocated by the EC will be exclusively awarded to beneficiaries from the public sector and to small and medium sized enterprises (SMEs), EFPIA partners will meet their budgetary obligations through in kind contributions.
For more information, please see the websites of IMI, EFPIA and the European Commission.
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
the identification of patients at high risk of diabetes complications
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.